USPSTF applies this recommendation to U.S. men who do not have symptoms that are highly suspicious for prostate cancer, regardless of age, race or family history. The task force concluded that scientific evidence does not support the common belief that PSA-based early detection of prostate cancer prolongs lives.
The findings of the two largest trials on the use of the screening highlight the uncertainty that remains about the precise effect that screening may have. The USPSTF concludes that there is moderate certainty that the harms of PSA-based screening for prostate cancer outweigh the benefits.
Related Articles on Quality:
Medical Error Victim’s Family Joins Chicago’s Patient Safety Committee
California Hospital Assn Launches Campaign to Market Quality Improvement Efforts
U Iowa Health to Settle Two Medical Malpractice Lawsuits for Combined $391k
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
